[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fuqqPgohifOu3yQMZGIdl2tgG__1i2Z-fM7g7ccvylJM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":39,"rows":46},"Uludag University",[4],127,false,32,0,16655,2,117,[14,17,19,22,24,27,29,31],{"name":15,"count":16},"Pain",6,{"name":18,"count":16},"Pain Management",{"name":20,"count":21},"Postoperative Pain",4,{"name":23,"count":21},"Anxiety",{"name":25,"count":26},"Analgesia",3,{"name":28,"count":26},"Anesthesia",{"name":30,"count":26},"Virtual Reality",{"name":32,"count":26},"Endometriosis",[34],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT07350018","Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome","2027-02-20","Poractant alfa",[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,73,91,120,138,156,174,201,219,248,273,299,325,352,370,396,422],{"intervention":38,"totalTrials":48,"cells":49},1,{"EARLY_PHASE1":50,"PHASE1":52,"PHASE2":54,"PHASE3":56,"PHASE4":58,"NA":71},{"trials":51,"activeCount":9},[],{"trials":53,"activeCount":9},[],{"trials":55,"activeCount":9},[],{"trials":57,"activeCount":9},[],{"trials":59,"activeCount":48,"soonestReadout":37},[60],{"nctId":35,"briefTitle":36,"status":61,"phases":62,"primaryCompletion":37,"completion":37,"start":63,"enrollment":64,"conditions":65,"interventions":69},"RECRUITING",[44],"2026-01-20",234,[66,67,68],"Respiratory Distress Syndrome in Premature Infants","Respiratory Distress Syndrome (RDS)","Surfactant",[38,70],"Calfactant",{"trials":72,"activeCount":9},[],{"intervention":70,"totalTrials":48,"cells":74},{"EARLY_PHASE1":75,"PHASE1":77,"PHASE2":79,"PHASE3":81,"PHASE4":83,"NA":89},{"trials":76,"activeCount":9},[],{"trials":78,"activeCount":9},[],{"trials":80,"activeCount":9},[],{"trials":82,"activeCount":9},[],{"trials":84,"activeCount":48,"soonestReadout":37},[85],{"nctId":35,"briefTitle":36,"status":61,"phases":86,"primaryCompletion":37,"completion":37,"start":63,"enrollment":64,"conditions":87,"interventions":88},[44],[66,67,68],[38,70],{"trials":90,"activeCount":9},[],{"intervention":92,"totalTrials":48,"cells":93},"Remifentanil",{"EARLY_PHASE1":94,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":102,"NA":118},{"trials":95,"activeCount":9},[],{"trials":97,"activeCount":9},[],{"trials":99,"activeCount":9},[],{"trials":101,"activeCount":9},[],{"trials":103,"activeCount":9},[104],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":114},"NCT02631135","Cognitive Functions After TIVA With Dexmedetomidine","COMPLETED",[44],"2008-10","2008-01",40,[113],"Postoperative Confusion",[92,115,116,117],"Propofol","Dexmedetomidine","Rocuronium",{"trials":119,"activeCount":9},[],{"intervention":115,"totalTrials":48,"cells":121},{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":130,"NA":136},{"trials":123,"activeCount":9},[],{"trials":125,"activeCount":9},[],{"trials":127,"activeCount":9},[],{"trials":129,"activeCount":9},[],{"trials":131,"activeCount":9},[132],{"nctId":105,"briefTitle":106,"status":107,"phases":133,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":134,"interventions":135},[44],[113],[92,115,116,117],{"trials":137,"activeCount":9},[],{"intervention":116,"totalTrials":48,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":154},{"trials":141,"activeCount":9},[],{"trials":143,"activeCount":9},[],{"trials":145,"activeCount":9},[],{"trials":147,"activeCount":9},[],{"trials":149,"activeCount":9},[150],{"nctId":105,"briefTitle":106,"status":107,"phases":151,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":152,"interventions":153},[44],[113],[92,115,116,117],{"trials":155,"activeCount":9},[],{"intervention":117,"totalTrials":48,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":164,"PHASE4":166,"NA":172},{"trials":159,"activeCount":9},[],{"trials":161,"activeCount":9},[],{"trials":163,"activeCount":9},[],{"trials":165,"activeCount":9},[],{"trials":167,"activeCount":9},[168],{"nctId":105,"briefTitle":106,"status":107,"phases":169,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":170,"interventions":171},[44],[113],[92,115,116,117],{"trials":173,"activeCount":9},[],{"intervention":175,"totalTrials":48,"cells":176},"Levobupivacaine",{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":183,"PHASE4":185,"NA":199},{"trials":178,"activeCount":9},[],{"trials":180,"activeCount":9},[],{"trials":182,"activeCount":9},[],{"trials":184,"activeCount":9},[],{"trials":186,"activeCount":9},[187],{"nctId":188,"briefTitle":189,"status":107,"phases":190,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":197},"NCT02497040","The Effects of Scalp Block With Bupivacaine Versus Levobupivacaine",[44],"2009-03","2009-04","2008-03",90,[196],"Hypertension",[175,198],"Bupivacaine",{"trials":200,"activeCount":9},[],{"intervention":198,"totalTrials":48,"cells":202},{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":207,"PHASE3":209,"PHASE4":211,"NA":217},{"trials":204,"activeCount":9},[],{"trials":206,"activeCount":9},[],{"trials":208,"activeCount":9},[],{"trials":210,"activeCount":9},[],{"trials":212,"activeCount":9},[213],{"nctId":188,"briefTitle":189,"status":107,"phases":214,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":215,"interventions":216},[44],[196],[175,198],{"trials":218,"activeCount":9},[],{"intervention":220,"totalTrials":48,"cells":221},"Ankaferd Blood Stopper",{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":230,"NA":232},{"trials":223,"activeCount":9},[],{"trials":225,"activeCount":9},[],{"trials":227,"activeCount":9},[],{"trials":229,"activeCount":9},[],{"trials":231,"activeCount":9},[],{"trials":233,"activeCount":9},[234],{"nctId":235,"briefTitle":236,"status":237,"phases":238,"primaryCompletion":239,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":247},"NCT05438771","The Effects of Ankaferd Blood Stopper","UNKNOWN",[45],"2023-06-02","2021-06-01",66,[243,244,245,246],"Colon Cancer","Oral Mucositis","Nurse's Role","Chemotherapy Effect",[220],{"intervention":249,"totalTrials":48,"cells":250},"Gynoflor",{"EARLY_PHASE1":251,"PHASE1":253,"PHASE2":255,"PHASE3":257,"PHASE4":259,"NA":261},{"trials":252,"activeCount":9},[],{"trials":254,"activeCount":9},[],{"trials":256,"activeCount":9},[],{"trials":258,"activeCount":9},[],{"trials":260,"activeCount":9},[],{"trials":262,"activeCount":9},[263],{"nctId":264,"briefTitle":265,"status":237,"phases":266,"primaryCompletion":267,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":272},"NCT04044599","Lactobacillus for Luteal Phase Support",[45],"2020-06-01","2020-03-30",200,[271],"IVF",[249],{"intervention":274,"totalTrials":48,"cells":275},"PTEN-AKT-FOXO3 Gene Expression",{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":284,"NA":286},{"trials":277,"activeCount":9},[],{"trials":279,"activeCount":9},[],{"trials":281,"activeCount":9},[],{"trials":283,"activeCount":9},[],{"trials":285,"activeCount":9},[],{"trials":287,"activeCount":9},[288],{"nctId":289,"briefTitle":290,"status":237,"phases":291,"primaryCompletion":292,"completion":293,"start":294,"enrollment":295,"conditions":296,"interventions":298},"NCT04058912","PTEN-AKT-FOXO3 Gene Expression Relation With Low-ovarian Reserve in Endometriomas",[],"2020-05-27","2020-06-30","2019-05-27",60,[297],"Ovarian Reserve, Endometrioma, PTEN-AKT-FOXO3 Gene Expression",[274],{"intervention":300,"totalTrials":48,"cells":301},"oral contraceptive pill, oral progesterone",{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":308,"PHASE4":310,"NA":312},{"trials":303,"activeCount":9},[],{"trials":305,"activeCount":9},[],{"trials":307,"activeCount":9},[],{"trials":309,"activeCount":9},[],{"trials":311,"activeCount":9},[],{"trials":313,"activeCount":9},[314],{"nctId":315,"briefTitle":316,"status":237,"phases":317,"primaryCompletion":318,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":324},"NCT03620838","Endometrioma Per se Versus Treatment Related Reduction in Ovarian Reserve (ERROR-2 Trial)",[],"2020-09-01","2019-03-01",250,[322,323],"Ovarian Reserve","Endometrioma",[300],{"intervention":326,"totalTrials":48,"cells":327},"Letrozole 2.5mg",{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":336,"NA":338},{"trials":329,"activeCount":9},[],{"trials":331,"activeCount":9},[],{"trials":333,"activeCount":9},[],{"trials":335,"activeCount":9},[],{"trials":337,"activeCount":9},[],{"trials":339,"activeCount":9},[340],{"nctId":341,"briefTitle":342,"status":107,"phases":343,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":350},"NCT06413771","Only Gonadotropin Vs. Letrozole Combined Gonadotropin Stimulation in IUI Cycles",[45],"2024-01-01","2024-02-01","2023-01-01",131,[349],"Infertility Unexplained",[326,351],"Gonadotropin",{"intervention":351,"totalTrials":48,"cells":353},{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":358,"PHASE3":360,"PHASE4":362,"NA":364},{"trials":355,"activeCount":9},[],{"trials":357,"activeCount":9},[],{"trials":359,"activeCount":9},[],{"trials":361,"activeCount":9},[],{"trials":363,"activeCount":9},[],{"trials":365,"activeCount":9},[366],{"nctId":341,"briefTitle":342,"status":107,"phases":367,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":368,"interventions":369},[45],[349],[326,351],{"intervention":371,"totalTrials":48,"cells":372},"Autologous Platelet-Rich Plasma",{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":379,"PHASE4":381,"NA":383},{"trials":374,"activeCount":9},[],{"trials":376,"activeCount":9},[],{"trials":378,"activeCount":9},[],{"trials":380,"activeCount":9},[],{"trials":382,"activeCount":9},[],{"trials":384,"activeCount":9},[385],{"nctId":386,"briefTitle":387,"status":107,"phases":388,"primaryCompletion":389,"completion":390,"start":391,"enrollment":392,"conditions":393,"interventions":395},"NCT07330713","Platelet-Rich Plasma for Acute Nonarteritic Anterior Ischemic Optic Neuropathy: A Prospective Randomized Controlled Study",[45],"2024-01-31","2024-05-31","2022-01-01",31,[394],"Nonarteritic Anterior Ischemic Optic Neuropathy",[371],{"intervention":397,"totalTrials":48,"cells":398},"Dienogest Pill",{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":405,"PHASE4":407,"NA":409},{"trials":400,"activeCount":9},[],{"trials":402,"activeCount":9},[],{"trials":404,"activeCount":9},[],{"trials":406,"activeCount":9},[],{"trials":408,"activeCount":9},[],{"trials":410,"activeCount":9},[411],{"nctId":412,"briefTitle":413,"status":107,"phases":414,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":419,"interventions":420},"NCT05476172","The Effect of Dienogest vs. Norethindrone Acetate Treatment in Endometriosis",[45],"2023-05-30","2023-06-30","2021-04-01",70,[32],[397,421],"Norethindrone Acetate",{"intervention":421,"totalTrials":48,"cells":423},{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":430,"PHASE4":432,"NA":434},{"trials":425,"activeCount":9},[],{"trials":427,"activeCount":9},[],{"trials":429,"activeCount":9},[],{"trials":431,"activeCount":9},[],{"trials":433,"activeCount":9},[],{"trials":435,"activeCount":9},[436],{"nctId":412,"briefTitle":413,"status":107,"phases":437,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":438,"interventions":439},[45],[32],[397,421]]